29 EMMONS DRIVE, PRINCETON, NJ
Annual Report to Security Holders
Soligenix, Inc. Increases Offering Amount by $2.5 Million Under Sales Agreement
News
Soligenix, Inc. Increases Offering Amount by $2,956,000 Under Sales Agreement
Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
Other Events
Soligenix, Inc. Enters At Market Issuance Sales Agreement for $3.45M
Soligenix Regains Compliance with Nasdaq Shareholders' Equity Requirement
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRER14A
PRE 14A
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload